RGNX · REGENXBIO Inc.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Cap structure and valuation

Cap structure
SP	$9.66
SO	66.0M
Options	11.8M
Warrants	1.1M
FD SO	79.0M
MC	$762.9M

Cash	$36.5M
Total debt	—
EV	$726.5M

TTM Multiples
EV / Revenue	4.2x
EV / EBITDA	—
MC / Net Income	—
EV / FCF	—
MC / FCF	—

Ownership & coverage
Institutional	65.5%
Insiders	6.3%
# Institutions	232
Analysts	11
Consensus	Buy
Avg target	$23.73

Short % float	13.1%
Days to cover	5.32

MC = SP × FD SO. EV = MC + Debt − Cash. SP = previous yfinance close. Balance-sheet figures as of 2026-07-31. Multiples use TTM (sum of last 4 quarters); shown as "—" when the denominator is zero or negative, or when fewer than four quarters are reported — a partial sum is not a trailing twelve months. Ownership & coverage per Yahoo Finance as of 2026-08-28 — institutional % is 13F-based, so it can lag a quarter and exceed 100% on share-count timing. Short interest per FINRA bi-monthly reporting, as of 2026-08-14; the float denominator can be unreliable on tiny floats.

Financial statements

	6/30/26	3/31/26	12/31/25	9/30/25
Total Revenue	108.02	6.39	30.34	29.73
Revenue YoY %	405.7%	(92.8%)	43.0%	22.9%

SG&A	21.62	21.31	22.38	20.25
R&D	56.09	57.34	59.61	56.10

Operating Income	29.26	(83.36)	(57.64)	(52.41)
Operating Income YoY %	146.2%	(787.4%)	(12.2%)	15.6%
Operating Margin %	27.1%	(1304.0%)	(190.0%)	(176.3%)
EBITDA	33.02	(79.50)	(53.77)	(48.52)
EBITDA Margin %	30.6%	(1243.6%)	(177.2%)	(163.2%)

Interest Expense	7.79	8.71	12.28	13.17
Other Income / (Expense)	1.24	2.02	2.76	3.64
Pretax Income	22.71	(90.05)	(67.15)	(61.94)
Net Income	22.71	(90.05)	(67.15)	(61.94)
Net Margin %	21.0%	(1408.6%)	(221.3%)	(208.3%)

Diluted EPS	$0.43	-$1.72	-$1.30	-$1.20
Basic EPS	$0.43	-$1.72	-$1.30	-$1.20
Diluted Avg Shares	53.0	52.4	—	51.7
Basic Avg Shares	52.8	52.4	—	51.7

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Total Revenue	174.48	170.44	83.33	90.24	112.72
Revenue YoY %	2.4%	104.5%	(7.7%)	(19.9%)	—
Cost of Revenue	—	—	33.57	37.21	54.55
Gross Profit	—	—	49.76	53.03	58.18
Gross Profit YoY %	—	—	(6.2%)	(8.9%)	—
Gross Margin %	—	—	59.7%	58.8%	51.6%

SG&A	85.56	82.86	76.62	88.49	85.28
R&D	229.14	228.30	208.52	232.27	242.45
Operating Expense	—	—	283.11	321.16	321.06

Operating Income	(164.15)	(161.20)	(233.35)	(268.13)	(262.88)
Operating Income YoY %	(1.8%)	30.9%	13.0%	(2.0%)	—
Operating Margin %	(94.1%)	(94.6%)	(280.0%)	(297.1%)	(233.2%)
EBITDA	(148.78)	(145.58)	(217.13)	(250.81)	(249.97)
EBITDA Margin %	(85.3%)	(85.4%)	(260.6%)	(277.9%)	(221.8%)

Interest Expense	41.95	45.01	12.66	6.86	23.25
Other Income / (Expense)	9.66	12.33	18.90	11.34	5.72
Pretax Income	(196.43)	(193.88)	(227.10)	(263.65)	(280.40)
Tax Provision	—	0.00	0.00	(0.15)	(0.08)
Net Income	(196.43)	(193.88)	(227.10)	(263.49)	(280.32)
Net Margin %	(112.6%)	(113.8%)	(272.5%)	(292.0%)	(248.7%)

Diluted EPS	-$3.79	-$3.76	-$4.59	-$6.02	-$6.50
Basic EPS	-$3.79	-$3.76	-$4.59	-$6.02	-$6.50
Diluted Avg Shares	53.0	51.6	49.5	43.7	43.2
Basic Avg Shares	52.8	51.6	49.5	43.7	43.2

	6/30/26	3/31/26	12/31/25	9/30/25
Cash & Equivalents	36.49	15.23	34.47	58.80
Short-term Investments	69.03	135.26	195.60	215.40
Receivables	106.75	10.04	26.38	25.35
Other Current Assets	23.89	25.99	24.83	32.41
Total Current Assets	236.16	186.52	281.28	331.97

Net PPE	98.45	101.87	104.86	107.52
Operating Lease ROU	43.87	45.54	47.16	48.82
Long-term Investments	—	—	10.79	27.84
Other Assets	8.14	7.96	8.96	9.06
Total Assets	386.62	341.89	453.03	525.20

Accounts Payable	15.55	21.21	21.36	22.27
Current Lease Liabilities	7.36	7.87	8.29	9.07
Other Current Liabilities	59.72	42.04	88.45	93.23
Total Current Liabilities	82.62	71.11	118.09	124.57
Long-term Lease Liabilities	61.60	63.20	65.22	67.43
Other Liabilities	170.64	186.50	166.99	171.75
Total Liabilities	314.85	320.81	350.30	363.75

Retained Earnings	(1,193.37)	(1,216.08)	(1,126.03)	(1,058.88)
Total Equity	71.77	21.08	102.73	161.45

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Cash & Equivalents	36.49	34.47	57.53	34.52	96.95
Short-term Investments	69.03	195.60	177.16	240.74	267.69
Receivables	106.75	26.38	20.47	24.79	28.08
Other Current Assets	23.89	24.83	22.84	34.92	23.25
Total Current Assets	236.16	281.28	278.00	334.97	415.98

Net PPE	98.45	104.86	117.59	132.10	141.69
Operating Lease ROU	43.87	47.16	53.72	60.49	65.12
Long-term Investments	—	10.79	10.18	38.87	200.56
Other Assets	8.14	8.96	6.50	7.54	9.93
Total Assets	386.62	453.03	465.99	573.97	833.27

Accounts Payable	15.55	21.36	22.80	22.79	27.21
Current Lease Liabilities	7.36	8.29	7.90	7.07	6.00
Other Current Liabilities	59.72	88.45	72.49	100.42	97.22
Total Current Liabilities	82.62	118.09	103.19	130.27	130.43
Long-term Lease Liabilities	61.60	65.22	74.13	82.22	88.80
Other Liabilities	170.64	166.99	29.01	49.73	97.84
Total Liabilities	314.85	350.30	206.34	262.23	317.07

Retained Earnings	(1,193.37)	(1,126.03)	(932.15)	(705.05)	(441.55)
Total Equity	71.77	102.73	259.65	311.74	516.20

	6/30/26	3/31/26	12/31/25	9/30/25
Net Income	22.71	(90.05)	(67.15)	(61.94)
D&A	3.76	3.86	3.87	3.89
Stock-Based Comp	9.05	8.62	8.38	9.00
Δ Working Cap & Other	(97.76)	1.39	2.62	(6.90)
Operating Cash Flow	(62.24)	(76.19)	(52.29)	(55.96)

CapEx	(0.76)	(1.24)	(0.51)	(0.49)
Other Investing	66.69	71.82	38.05	42.78
Investing Cash Flow	65.92	70.59	37.54	42.29

Other Financing	17.57	(13.64)	(9.58)	(7.08)
Financing Cash Flow	17.57	(13.64)	(9.58)	(7.08)

Free Cash Flow	(63.00)	(77.42)	(52.80)	(56.45)

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Net Income	(196.43)	(193.88)	(227.10)	(263.49)	(280.32)
D&A	15.37	15.62	16.21	17.32	12.91
Stock-Based Comp	35.04	34.56	38.46	40.27	40.79
Δ Working Cap & Other	(100.65)	19.74	(0.70)	(12.50)	19.14
Operating Cash Flow	(246.67)	(123.96)	(173.12)	(218.41)	(207.49)

CapEx	(2.99)	(2.41)	(2.44)	(9.96)	(30.72)
Other Investing	219.33	(13.45)	105.88	200.90	18.80
Investing Cash Flow	216.34	(15.87)	103.45	190.94	(11.93)

Other Financing	(12.73)	116.77	92.68	(34.97)	(28.84)
Financing Cash Flow	(12.73)	116.77	92.68	(34.97)	(28.84)

Free Cash Flow	(249.67)	(126.38)	(175.56)	(228.37)	(238.21)

	6/30/26	3/31/26	12/31/25	9/30/25
Current Ratio	2.86	2.62	2.38	2.66
Quick Ratio	—	—	—	—
Debt / Equity	—	—	—	—
EBITDA Margin %	30.6%	(1243.6%)	(177.2%)	(163.2%)
Working Capital	153.54	115.41	163.19	207.40
Net Debt	—	—	—	—
ROE %	31.6%	(427.1%)	(65.4%)	(38.4%)
ROA %	5.9%	(26.3%)	(14.8%)	(11.8%)

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Current Ratio	2.86	2.38	2.69	2.57	3.19
Quick Ratio	—	—	—	—	—
Debt / Equity	—	—	—	—	—
EBITDA Margin %	(85.3%)	(85.4%)	(260.6%)	(277.9%)	(221.8%)
Working Capital	153.54	163.19	174.81	204.70	285.54
Net Debt	—	—	—	—	—
ROE %	(273.7%)	(188.7%)	(87.5%)	(84.5%)	(54.3%)
ROA %	(50.8%)	(42.8%)	(48.7%)	(45.9%)	(33.6%)

Insider activity (last 2 years)

Date Filed	Reporter	Relationship	Trans. Date	Code	Shares	Price	Total Value
2026-08-27	Ciongoli Gregory Austin	Director	2026-08-27	P	53,407	$9.36	$499,676
2026-08-27	Ciongoli Gregory Austin	Director	2026-08-26	P	49,196	$9.14	$449,706
2026-08-27	Ciongoli Gregory Austin	Director	2026-08-25	A	15,432	—	$0
2026-08-27	Ciongoli Gregory Austin	Director	2026-08-25	A	69,609	—	$0
2026-08-04	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-08-01	F	(7,468)	$9.69	-$72,365
2026-08-04	Christmas Patrick J.	Officer (Chief Strategy & Legal Officer)	2026-08-01	F	(4,699)	$9.69	-$45,533
2026-07-06	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-07-02	M	2,161	$7.86	$16,985
2026-07-06	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-07-02	S	(2,161)	$13.64	-$29,476
2026-07-06	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-07-02	M	(2,161)	—	$-0
2026-07-06	Simpson Curran	Director, Officer (Chief Executive Officer)	2026-07-01	F	(6,818)	$13.09	-$89,248
2026-07-06	Simpson Curran	Director, Officer (Chief Executive Officer)	2026-06-30	A	1,453	$10.18	$14,792
2026-07-06	Simpson Curran	Director, Officer (Chief Executive Officer)	2025-12-31	A	951	$7.00	$6,653
2026-07-01	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-07-01	M	36,725	$7.86	$288,658
2026-07-01	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-07-01	S	(36,725)	$12.86	-$472,284
2026-07-01	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-07-01	M	(36,725)	—	$-0
2026-07-01	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-06-29	S	(19,608)	$11.04	-$216,472
2026-06-02	Tasse Daniel	Director	2026-05-29	A	9,807	—	$0
2026-06-02	Tasse Daniel	Director	2026-05-29	A	46,600	—	$0
2026-06-02	STUMP DAVID C	Director	2026-05-29	A	9,807	—	$0
2026-06-02	STUMP DAVID C	Director	2026-05-29	A	46,600	—	$0
2026-06-02	Zachary Jennifer	Director	2026-05-29	A	9,807	—	$0
2026-06-02	Zachary Jennifer	Director	2026-05-29	A	46,600	—	$0
2026-06-02	Mills Kenneth T.	Director	2026-05-29	A	9,807	—	$0
2026-06-02	Mills Kenneth T.	Director	2026-05-29	A	46,600	—	$0
2026-06-02	MIGAUSKY GEORGE V	Director	2026-05-29	A	9,807	—	$0
2026-06-02	MIGAUSKY GEORGE V	Director	2026-05-29	A	46,600	—	$0
2026-06-02	KARABELAS ARGERIS N	Director	2026-05-29	A	9,807	—	$0
2026-06-02	KARABELAS ARGERIS N	Director	2026-05-29	A	46,600	—	$0
2026-06-02	Glucksmann Alexandra	Director	2026-05-29	A	9,807	—	$0
2026-06-02	Glucksmann Alexandra	Director	2026-05-29	A	46,600	—	$0
2026-06-02	Fox Allan M.	Director	2026-05-29	A	9,807	—	$0
2026-06-02	Fox Allan M.	Director	2026-05-29	A	46,600	—	$0
2026-06-02	Bennett Jean	Director	2026-05-29	A	9,807	—	$0
2026-06-02	Bennett Jean	Director	2026-05-29	A	46,600	—	$0
2026-05-13	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-05-11	S	(15,309)	$11.02	-$168,705
2026-03-12	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-03-10	S	(5,124)	$10.35	-$53,033
2026-02-03	Christmas Patrick J.	Officer (Chief Strategy & Legal Officer)	2026-02-01	F	(4,700)	$11.16	-$52,452
2026-02-03	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-02-01	F	(5,267)	$11.16	-$58,780
2026-01-29	Mills Kenneth T.	Director	2026-01-27	M	225,000	$13.09	$2,945,250
2026-01-29	Mills Kenneth T.	Director	2026-01-27	F	(221,753)	$13.41	-$2,973,708
2026-01-29	Mills Kenneth T.	Director	2026-01-27	M	(225,000)	—	$-0
2026-01-08	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-01-06	A	65,847	—	$0
2026-01-08	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-01-06	A	35,402	—	$0
2026-01-08	Malzahn Craig	Officer (Chief Technology Officer)	2026-01-06	A	65,847	—	$0
2026-01-08	Malzahn Craig	Officer (Chief Technology Officer)	2026-01-06	A	35,402	—	$0
2026-01-08	Simpson Curran	Director, Officer (Chief Executive Officer)	2026-01-06	A	144,864	—	$0
2026-01-08	Simpson Curran	Director, Officer (Chief Executive Officer)	2026-01-06	A	233,651	—	$0
2026-01-08	Christmas Patrick J.	Officer (Chief Strategy & Legal Officer)	2026-01-06	A	73,749	—	$0
2026-01-08	Christmas Patrick J.	Officer (Chief Strategy & Legal Officer)	2026-01-06	A	39,650	—	$0
2026-01-08	Chan Mitchell	Officer (Chief Financial Officer)	2026-01-06	A	73,749	—	$0
2026-01-08	Chan Mitchell	Officer (Chief Financial Officer)	2026-01-06	A	39,650	—	$0
2026-01-06	Simpson Curran	Director, Officer (Chief Executive Officer)	2026-01-02	F	(18,559)	$14.40	-$267,250
2026-01-06	Malzahn Craig	Officer (Chief Technology Officer)	2026-01-02	F	(1,238)	$14.40	-$17,827
2026-01-06	Christmas Patrick J.	Officer (Chief Strategy & Legal Officer)	2026-01-02	F	(9,793)	$14.40	-$141,019
2026-01-06	PAKOLA STEVE	Officer (Chief Medical Officer)	2026-01-02	F	(18,247)	$14.40	-$262,757
2025-10-10	Simpson Curran	Director, Officer (Chief Executive Officer)	2025-10-09	S	(20,811)	$12.62	-$262,635
2025-10-01	Simpson Curran	Director, Officer (Chief Executive Officer)	2025-09-29	S	(7,624)	$10.03	-$76,469
2025-09-12	Simpson Curran	Director, Officer (Chief Executive Officer)	2025-09-10	S	(7,734)	$10.02	-$77,495
2025-09-03	Malzahn Craig	Officer (Chief Technology Officer)	2025-09-01	F	(234)	$8.93	-$2,090
2025-09-03	Chan Mitchell	Officer (Chief Financial Officer)	2025-09-01	F	(4,901)	$8.93	-$43,766
2025-08-04	Christmas Patrick J.	Officer (Chief Strategy & Legal Officer)	2025-08-01	F	(4,699)	$8.19	-$38,485
2025-07-03	Simpson Curran	Director, Officer (Chief Executive Officer)	2025-07-01	F	(4,701)	$8.23	-$38,689
2025-06-03	Fox Allan M.	Director	2025-05-30	A	7,768	—	$0
2025-06-03	Fox Allan M.	Director	2025-05-30	A	39,815	—	$0
2025-06-03	Zachary Jennifer	Director	2025-05-30	A	7,768	—	$0
2025-06-03	Zachary Jennifer	Director	2025-05-30	A	39,815	—	$0
2025-06-03	Tasse Daniel	Director	2025-05-30	A	7,768	—	$0
2025-06-03	Tasse Daniel	Director	2025-05-30	A	39,815	—	$0
2025-06-03	STUMP DAVID C	Director	2025-05-30	A	7,768	—	$0
2025-06-03	STUMP DAVID C	Director	2025-05-30	A	39,815	—	$0
2025-06-03	Mills Kenneth T.	Director	2025-05-30	A	7,768	—	$0
2025-06-03	Mills Kenneth T.	Director	2025-05-30	A	39,815	—	$0
2025-06-03	MIGAUSKY GEORGE V	Director	2025-05-30	A	7,768	—	$0
2025-06-03	MIGAUSKY GEORGE V	Director	2025-05-30	A	39,815	—	$0
2025-06-03	Glucksmann Alexandra	Director	2025-05-30	A	7,768	—	$0
2025-06-03	Glucksmann Alexandra	Director	2025-05-30	A	39,815	—	$0
2025-06-03	KARABELAS ARGERIS N	Director	2025-05-30	A	7,768	—	$0
2025-06-03	KARABELAS ARGERIS N	Director	2025-05-30	A	39,815	—	$0
2025-06-03	Bennett Jean	Director	2025-05-30	A	7,768	—	$0
2025-06-03	Bennett Jean	Director	2025-05-30	A	39,815	—	$0
2025-05-14	Mills Kenneth T.	Director	2025-05-12	M	20,602	$3.76	$77,464
2025-05-14	Mills Kenneth T.	Director	2025-05-12	S	(20,602)	$7.91	-$163,046
2025-05-14	Mills Kenneth T.	Director	2025-05-12	M	(20,602)	—	$-0
2025-04-04	Christmas Patrick J.	Officer (Chief Legal Officer)	2025-02-01	F	(4,700)	$8.07	-$37,929
2025-04-04	PAKOLA STEVE	Officer (Chief Medical Officer)	2025-02-01	F	(5,263)	$8.07	-$42,472
2025-04-04	Danos Olivier	Officer (Chief Scientific Officer)	2025-02-01	F	(5,452)	$8.07	-$43,998
2025-03-31	Mills Kenneth T.	Director	2025-03-27	M	30,752	$3.76	$115,628
2025-03-31	Mills Kenneth T.	Director	2025-03-27	M	(30,752)	—	$-0
2025-01-14	Simpson Curran	Director, Officer (Chief Executive Officer)	2025-01-02	A	478,606	—	$0
2025-01-06	PAKOLA STEVE	Officer (Chief Medical Officer)	2025-01-02	F	(13,891)	$7.73	-$107,377
2025-01-06	PAKOLA STEVE	Officer (Chief Medical Officer)	2025-01-02	A	64,293	—	$0
2025-01-06	PAKOLA STEVE	Officer (Chief Medical Officer)	2025-01-02	A	103,698	—	$0
2025-01-06	Danos Olivier	Officer (Chief Scientific Officer)	2025-01-02	F	(12,630)	$7.73	-$97,630
2025-01-06	Danos Olivier	Officer (Chief Scientific Officer)	2025-01-02	A	59,347	—	$0
2025-01-06	Danos Olivier	Officer (Chief Scientific Officer)	2025-01-02	A	95,721	—	$0
2025-01-06	Simpson Curran	Director, Officer (Chief Executive Officer)	2025-01-02	F	(11,917)	$7.73	-$92,118
2025-01-06	Simpson Curran	Director, Officer (Chief Executive Officer)	2025-01-02	A	98,912	—	$0
2025-01-06	Simpson Curran	Director, Officer (Chief Executive Officer)	2025-01-02	A	476,606	—	$0
2025-01-06	Chan Mitchell	Officer (Chief Financial Officer)	2025-01-02	A	62,547	—	$0
2025-01-06	Christmas Patrick J.	Officer (Chief Legal Officer)	2025-01-02	F	(11,395)	$7.73	-$88,083
2025-01-06	Christmas Patrick J.	Officer (Chief Legal Officer)	2025-01-02	A	223,350	—	$0
2024-10-02	KARABELAS ARGERIS N	Director	2024-10-01	M	10,000	$3.76	$37,600
2024-10-02	KARABELAS ARGERIS N	Director	2024-10-01	S	(10,000)	$10.11	-$101,052
2024-10-02	KARABELAS ARGERIS N	Director	2024-10-01	M	(10,000)	—	$-0
2024-09-18	Chan Mitchell	Officer (Chief Financial Officer)	2024-09-16	A	58,869	—	$0
2024-09-18	Chan Mitchell	Officer (Chief Financial Officer)	2024-09-16	A	289,362	—	$0
2024-09-04	KARABELAS ARGERIS N	Director	2024-09-03	M	10,000	$3.76	$37,600
2024-09-04	KARABELAS ARGERIS N	Director	2024-09-03	S	(9,300)	$11.50	-$106,950
2024-09-04	KARABELAS ARGERIS N	Director	2024-09-03	S	(700)	$12.34	-$8,638
2024-09-04	KARABELAS ARGERIS N	Director	2024-09-03	M	(10,000)	—	$-0